Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216264 | 0.75 | HSD17B10 (0.48) | HSD17B10TSHRHTR3EHTR3BCYP1A2 | |
| SCHEMBL30136182 | 0.74 | ADRB1 (0.43) | TSHRHTR1AHTR7HTR3AALDH1A1 | |
| SCHEMBL27957824 | 0.74 | ADRB1 (0.44) | TSHRALDH1A1KDM4ELMNANOTUM | |
| SCHEMBL29031422 | 0.73 | ADRB1 (0.53) | HTR1AHTR6MAPTMEN1KMT2A | |
| SCHEMBL28861560 | 0.71 | MGLL (0.42) | TSHRHTR1AHTR2ALMNAMAPT | |
| SCHEMBL28857529 | 0.70 | NCF1 (0.40) | HTR1ANCF1HTR2ACYP2A6 | |
| SCHEMBL30136220 | 0.70 | DRD2 (0.47) | HTR3EHTR3BHTR7HTR3AHTR6 | |
| SCHEMBL3517237 | 0.69 | HSD17B10 (0.47) | HSD17B10TSHRHTR3EHTR3BCYP1A2 | |
| SCHEMBL10972103 | 0.68 | HSD17B10 (0.42) | HSD17B10TSHRHTR3EHTR3BCYP1A2 | |
| SCHEMBL8355768 | 0.68 | HSD17B10 (0.42) | HSD17B10TSHRHTR3EHTR3BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103124774-B | Metal complex dye, photo-electric conversion element and photoelectrochemical cell | FUJIFILM CORP. (JP) | 2015-08-19 | — | — | CN | claimed |
| CN-103124774-A | Metal complex dye, photoelectric conversion element and photoelectrochemical cell | FUJIFILM CORP | 2013-05-29 | — | — | CN | claimed |
| CN-103124774-B | Metal complex dye, photo-electric conversion element and photoelectrochemical cell | FUJIFILM CORP. (JP) | 2015-08-19 | — | — | CN | disclosed |
| CN-103124774-B | Metal complex dye, photo-electric conversion element and photoelectrochemical cell | FUJIFILM CORP. (JP) | 2015-08-19 | — | — | CN | disclosed |
| CN-103124774-A | Metal complex dye, photoelectric conversion element and photoelectrochemical cell | FUJIFILM CORP | 2013-05-29 | — | — | CN | disclosed |
| CN-103124774-A | Metal complex dye, photoelectric conversion element and photoelectrochemical cell | FUJIFILM CORP | 2013-05-29 | — | — | CN | disclosed |
| WO-2012017868-A1 | METAL COMPLEX DYE, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL | 富士フイルム株式会社 (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20110059070-A1 | Combination therapy for tumoral desease treatment | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-03-10 | — | — | US | disclosed |
| EP-2061464-A2 | COMBINATION THERAPY FOR TUMORAL DISEASE TREATMENT | Ramot, at Tel Aviv University Ltd. (IL) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032324-A2 | COMBINATION THERAPY FOR TUMORAL DISEASE TREATMENT | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-03-20 | — | — | WO | disclosed |
| US-5861424-A | CATIONIC HETEROCYCLIC COMPOUNDS FOR TREATING CANCER | DANA FARBER CANCER INSTITUTE (US) | 1999-01-19 | — | — | US | disclosed |
| US-5670530-A | ADJUSTMENT SOLUBILITY OF RHODACYANINE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| US-5618831-A | RHODACYANINE DYES; TREATING MELANOMAS | FUJI PHOTO FILM CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| EP-0527494-B1 | Compositon containing rhodacyanine dyes for treating cancer | FUJI PHOTO FILM CO LTD (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5360803-A | Rhodocyanine dyes | DAN FARBER CANCER INSTITUTE (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0594697-A1 | NONLINEAR OPTICAL MATERIALS CONTAINING POLAR DISULFONE-FUNCTIONALIZED MOLECULES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0527494-A1 | Compositon containing rhodacyanine dyes for treating cancer | Fuji Photo Film Co., Ltd. (JP) | 1993-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059070-A1 | Combination therapy for tumoral desease treatment | MME, HSP90B1, CD68 | HSD17B10 3330/4885TSHR 4263/4885HTR3E 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.